Immunsystemet vid ateroskleros. Immunmodulerande eller antiinflammatorisk behandling som har effekt mot ateroskleros och dess komplikationer behövs för att säkerställa hypotesen
Engelsk titel: The immune system in atherosclerosis. Immunomodulatory or anti-inflammatory treatment that is effective against atherosclerosis and its complications are needed to ensure the hypothesis
Läs online
Författare:
Frostegård, Johan
Email: johan.frostegard@ki.se
Språk: Swe
Antal referenser: 73
Dokumenttyp:
Översikt
UI-nummer: 13127106
Sammanfattning
Atherosclerosis and its consequence cardiovascular disease (CVD) represent dominating causes of death in the Western world and increasingly in developing countries. Atherosclerosis can be described as a chronic inflammation, where activated immune competent cells include T-cells, monocytes/macrophages and dendritic cells. The cause of inflammation and immune activation is not clear, but candidates include oxidized and/or enzymatically modified low density lipoprotein (OxLDL), dead cells, heat shock proteins (HSP), infections and also an inefficient protective immune response with low levels of natural antibodies against epitopes as phosphorylcholine in oxLDL. Available evidence indicates that atherosclerosis per se can be seen as a part of normal human aging, but that its consequences in the form of CVD can be substantially postponed.
To prove that inflammation and immunological factors have a causative role in CVD, successful clinical trials with anti-inflammatory and/or immune modulatory treatment are needed.